Get the Stockscreener App
42.02
1.94%
0.80
Verona Pharma Plc Adr stock is traded at $42.02, with a volume of 726.90K.
It is up +1.94% in the last 24 hours and up +8.16% over the past month.
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
See More
Previous Close:
$41.22
Open:
$40.1
24h Volume:
726.90K
Relative Volume:
0.75
Market Cap:
$3.44B
Revenue:
-
Net Income/Loss:
$-153.72M
P/E Ratio:
-75.04
EPS:
-0.56
Net Cash Flow:
$-103.81M
1W Performance:
+1.45%
1M Performance:
+8.16%
6M Performance:
+186.04%
1Y Performance:
+153.44%
1-Day Range:
$40.10
$42.86
1-Week Range:
$39.67
$43.73
52-Week Range:
$11.39
$43.73
Verona Pharma Plc Adr Stock (VRNA) Company Profile
Name
Verona Pharma Plc Adr
Sector
Industry
Phone
011-44-0-2032834200
Address
3 MORE LONDON RIVERSIDE, LONDON
Compare VRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
42.02 | 3.44B | 0 | -153.72M | -103.81M | -2.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-24 | Initiated | Wells Fargo | Overweight |
| May-22-23 | Resumed | Jefferies | Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-26-22 | Initiated | Piper Sandler | Overweight |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Jefferies | Buy |
| Aug-10-20 | Initiated | Canaccord Genuity | Buy |
| Apr-18-19 | Initiated | BTIG Research | Buy |
View All
Verona Pharma Plc Adr Stock (VRNA) Latest News
Verona Pharma CFO Mark Hahn sells shares worth $4.4 million - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $4.36 million - Investing.com
Verona Pharma's CFO Mark Hahn sells shares worth $566,821 - Investing.com India
Verona Pharma's CFO Mark Hahn sells shares worth $566,821 By Investing.com - Investing.com South Africa
Verona Pharma CEO David Zaccardelli sells shares worth $627,233 - Investing.com
Verona Pharma CFO sells shares totaling $12,000 - Investing.com India
Verona Pharma's chief medical officer sells $1.18 million in shares - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $8,000 - Investing.com
Verona Pharma director David Ebsworth buys $88,800 in shares - Investing.com India
Verona Pharma director Christina Ackermann acquires $198,385 in shares - Investing.com
Verona Pharma CFO Mark Hahn sells shares worth $568,386 - Investing.com
Verona Pharma CEO David Zaccardelli sells $618,657 in shares - Investing.com
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre By Investing.com - Investing.com Nigeria
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre - Investing.com India
Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday - Investing.com Nigeria
Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday By Investing.com - Investing.com South Africa
Verona Pharma ADR earnings matched, revenue topped estimates By Investing.com - Investing.com UK
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Verona Pharma CFO Mark Hahn sells shares worth $632,760 - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $633,895 - Investing.com India
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart
5 Biotech Stocks Likely To Outperform As Industry Prospects Look Bright - Barchart
Verona Pharma CEO David Zaccardelli sells $2.25 million in shares - Investing.com India
Verona Pharma CEO David Zaccardelli sells $2.25 million in shares By Investing.com - Investing.com South Africa
Verona Pharma CFO Mark Hahn sells shares worth $2.3 million By Investing.com - Investing.com South Africa
Verona Pharma CFO Mark Hahn sells shares worth $2.3 million - Investing.com India
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance
Market Insights: Verona Pharma Plc ADR (VRNA)’s Notable Drop of -0.55, Closing at 34.07 - The Dwinnex
Verona Pharma Plc ADR [VRNA] Insider Activity: An Update for Investors - Knox Daily
Phathom Pharmaceuticals Inc [PHAT] Investment Appeal on the Rise - Knox Daily
Verona Pharma Plc ADR (VRNA) stock: A year of ups and downs - US Post News
VRNA Shares Experience Decline in Value - Knox Daily
Financial Metrics Exploration: Understanding Verona Pharma Plc ADR (VRNA) Through Ratios - The Dwinnex
A stock that deserves closer examination: Verona Pharma Plc ADR (VRNA) - US Post News
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Wells Fargo gives an Overweight recommendation for Verona Pharma Plc ADR (VRNA) - Knox Daily
Verona Pharma Plc ADR’s (NASDAQ: VRNA) Stock Forecast: Increase To $38 In A Year - Stocks Register
Prepare Yourself for Liftoff: Verona Pharma Plc ADR (VRNA) - SETE News
Verona Pharma Plc ADR [VRNA] stock for 2,254,320 USD was sold by ZACCARDELLI DAVID - Knox Daily
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains? - Yahoo Finance
Cactus Inc [WHD] Records 50-Day SMA of $59.34 - Knox Daily
Verona Pharma stock soars to all-time high of $30.76 By Investing.com - Investing.com South Africa
Piper Sandler maintains Overweight rating on Verona Pharma shares By Investing.com - Investing.com South Africa
Sea Limited Sponsored ADR (SE) Stock Moves -0.17%: What You Should Know - Yahoo Finance
Verona Pharma stock soars to all-time high of $30.76 - Investing.com
VRNA’s Stock Market Adventure: 58.43% YTD Growth Amidst Volatility - The InvestChronicle
Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) Moves 6.2% Higher: Will This Strength Last? - Yahoo Finance
Tesla and Nvidia Lead Afternoon Market Cap Stock Movers on Thursday - Investing.com
MINISO Group Holding Limited Unsponsored ADR (MNSO) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Verona Pharma Plc ADR (VRNA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Investing in Verona Pharma Plc ADR (VRNA) might be a great opportunity, but the stock is a bit overvalued - US Post News
Verona Pharma Plc Adr Stock (VRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Verona Pharma Plc Adr Stock (VRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ZACCARDELLI DAVID | President and CEO |
Dec 06 '24 |
Sale |
5.01 |
162,800 |
815,400 |
14,204,752 |
| ZACCARDELLI DAVID | President and CEO |
Dec 04 '24 |
Sale |
5.00 |
67,608 |
338,162 |
15,007,816 |
| Hahn Mark W | Chief Financial Officer |
Dec 05 '24 |
Sale |
5.01 |
640,048 |
3,204,144 |
13,477,464 |
| Hahn Mark W | Chief Financial Officer |
Dec 06 '24 |
Sale |
5.01 |
183,728 |
920,312 |
13,293,736 |
| Hahn Mark W | Chief Financial Officer |
Dec 04 '24 |
Sale |
5.00 |
58,184 |
290,996 |
14,117,512 |
| Hahn Mark W | Chief Financial Officer |
Nov 29 '24 |
Sale |
5.01 |
98,704 |
494,142 |
14,177,296 |
| Hahn Mark W | Chief Financial Officer |
Nov 27 '24 |
Sale |
5.00 |
12,936 |
64,680 |
14,276,000 |
| Hahn Mark W | Chief Financial Officer |
Dec 02 '24 |
Sale |
5.00 |
1,600 |
8,000 |
14,175,696 |
| ZACCARDELLI DAVID | President and CEO |
Nov 29 '24 |
Sale |
5.01 |
98,888 |
495,033 |
15,078,624 |
| ZACCARDELLI DAVID | President and CEO |
Nov 27 '24 |
Sale |
5.00 |
23,240 |
116,200 |
15,177,512 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):